Aficamten not checked

Cytokinetics · CK-3773274

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2/3 trial completes
Trials
4 active
10 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Aficamten tablets, 5-20 mg daily, administered orally. Participants may continue on Aficamten until end of treatment criteria defined in the protocol is met.”In the company’s words, NCT04848506 on ClinicalTrials.gov
Tested for
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy, Symptomatic Hypertrophic Cardiomyopathy (HCM), Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Main trialPhase 3
“This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.”In the company’s words, NCT06081894 on ClinicalTrials.gov
Other names
CK-3773274

Other drugs for Symptomatic Hypertrophic Cardiomyopathy (HCM)

All 9 drugs for Symptomatic Hypertrophic Cardiomyopathy (HCM)

Coming up2

Changes1

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 Aug 2026 A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Phase 2/3Enrolling by invitation Mar 2029 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Phase 2/3Active, not recruiting Jan 2030 A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Phase 3Completed 10 Nov 2023 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Phase 3Completed 28 Feb 2025 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Phase 2Completed 28 Feb 2023 Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Phase 1Completed 3 Jan 2020 A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
Phase 1Completed 5 Aug 2021 Safety, Tolerability and Pharmacokinetics Study of CK-3773274
Phase 1Completed 14 Nov 2023 Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Phase 2Authorised not given Learning From Early Aficamten In HCM (LEAF-HCM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Aficamten

Following is part of Solo: you see every change to Aficamten the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in